Literature DB >> 8384651

Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling.

L Racioppi1, F Ronchese, L A Matis, R N Germain.   

Abstract

Clonal activation of CD4+ and CD8+ T lymphocytes depends on binding of peptide-major histocompatibility complex (MHC) molecule complexes by their alpha/beta receptors, eventually resulting in sufficient aggregation to initiate second messenger generation. The nature of intracellular signals resulting from such T cell receptor (TCR) occupancy is believed to be independent of the specific structure of the ligand being bound, and to vary quantitatively, not qualitatively, with the concentration of ligand offered and the affinity of the receptor for the peptide-MHC molecule complex. In contrast to the expectations of this model, the analysis of the response of a T helper type 1 clone to mutant E alpha E beta k molecules in the absence or presence of a peptide antigen revealed that peptide inhibited the interleukin 2 (IL-2) response to an otherwise allostimulatory mutant form of this MHC class II molecule. The inhibition was not due to competition for formation of alloantigen, it required TCR recognition of peptide-mutant MHC molecule complexes, and it decreased IL-2 production without affecting receptor-dependent IL-3, IL-2 receptor alpha, or size enlargement responses. This preferential reduction in IL-2 secretion could be correlated with the costimulatory signal dependence of this cytokine response, but could not be overcome by crosslinking the CD28 molecule on the T cell. These results define a new class of TCR ligands with mixed agonist/antagonist properties, and point to a ligand-related variation in the quality of clonotypic receptor signaling events or their integration with other signaling processes. It was also found that a single TCR ligand showed greatly different dose thresholds for the elicitation of distinct effector responses from a cloned T cell population. The observations that changes in ligand structure can result in qualitative alterations in the effects of receptor occupancy and that quantitative variations in ligand density can be translated into qualitative differences in T cell responses have important implications for models of intrathymic selection and control of the results of active immunization.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384651      PMCID: PMC2190984          DOI: 10.1084/jem.177.4.1047

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  77 in total

1.  The level of CD8 expression can determine the outcome of thymic selection.

Authors:  E A Robey; F Ramsdell; D Kioussis; W Sha; D Loh; R Axel; B J Fowlkes
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

2.  Contingent genetic regulatory events in T lymphocyte activation.

Authors:  G R Crabtree
Journal:  Science       Date:  1989-01-20       Impact factor: 47.728

3.  Differential regulatory signals delivered by antibody binding to the CD28 (Tp44) molecule during the activation of human T lymphocytes.

Authors:  N K Damle; L V Doyle; L S Grosmaire; J A Ledbetter
Journal:  J Immunol       Date:  1988-03-15       Impact factor: 5.422

4.  Peptide-mediated modulation of T-cell allorecognition.

Authors:  D D Eckels; J Gorski; J Rothbard; J R Lamb
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

5.  T helper cell subsets require the expression of distinct costimulatory signals by antigen-presenting cells.

Authors:  C T Weaver; C M Hawrylowicz; E R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

6.  In vivo competition between self peptides and foreign antigens in T-cell activation.

Authors:  L Adorini; S Muller; F Cardinaux; P V Lehmann; F Falcioni; Z A Nagy
Journal:  Nature       Date:  1988-08-18       Impact factor: 49.962

7.  Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28.

Authors:  J D Fraser; B A Irving; G R Crabtree; A Weiss
Journal:  Science       Date:  1991-01-18       Impact factor: 47.728

8.  Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells.

Authors:  Z Razi-Wolf; G J Freeman; F Galvin; B Benacerraf; L Nadler; H Reiser
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

9.  Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor.

Authors:  S Weber; A Traunecker; F Oliveri; W Gerhard; K Karjalainen
Journal:  Nature       Date:  1992-04-30       Impact factor: 49.962

10.  Synthetic peptides as antigens and competitors in recognition by H-2-restricted cytolytic T cells specific for HLA.

Authors:  J L Maryanski; P Pala; J C Cerottini; G Corradin
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

View more
  68 in total

Review 1.  The contributions of T-cell anergy to peripheral T-cell tolerance.

Authors:  R Lechler; J G Chai; F Marelli-Berg; G Lombardi
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

Review 2.  Signaling cascades: escape from kinetic proofreading.

Authors:  D MacGlashan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

Review 3.  T cell-mediated antigen presentation: a potential mechanism of infectious tolerance.

Authors:  M D Mannie
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

4.  Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells.

Authors:  Philip J Norris; Howell F Moffett; Christian Brander; Todd M Allen; Kristin M O'Sullivan; Lisa A Cosimi; Daniel E Kaufmann; Bruce D Walker; Eric S Rosenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2004-03       Impact factor: 2.205

Review 5.  T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Kate O'Brien; Bruno Gran; Abdolmohamad Rostami
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

6.  A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens.

Authors:  L B Nicholson; A Murtaza; B P Hafler; A Sette; V K Kuchroo
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

7.  Engagement of glycosylphosphatidylinositol-anchored proteins results in enhanced mouse and human invariant natural killer T cell responses.

Authors:  Lisa A Mannik; Ian Chin-Yee; Shayan Sharif; Luc Van Kaer; Terry L Delovitch; S M Mansour Haeryfar
Journal:  Immunology       Date:  2010-11-11       Impact factor: 7.397

Review 8.  Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

Authors:  Stefan Bittner; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 9.  Modulation of the immune response with T-cell epitopes: the ultimate goal for specific immunotherapy of autoimmune disease.

Authors:  P J Fairchild; C J Thorpe; P J Travers; D C Wraith
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

Review 10.  Suboptimal engagement of the T-cell receptor by a variety of peptide-MHC ligands triggers T-cell anergy.

Authors:  Scheherazade Sadegh-Nasseri; Sarat K Dalai; Laura C Korb Ferris; Saied Mirshahidi
Journal:  Immunology       Date:  2009-12-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.